Novo's CagriSema Shows Strong Dual Benefits in Diabetes Trial, But Faces Stiff Competition
Novo Nordisk's experimental combination therapy CagriSema has demonstrated superior blood sugar control and weight loss compared to its own blockbuster Wegovy in a major Phase 3 trial. However, the emerging data suggests it may still trail behind Eli Lilly's rival drug Zepbound in key efficacy measures, setting the stage for a fierce market battle.